Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 24, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction

Merck

Yes, but it isn't a worst-case scenario by any means.

Is Inflation a Threat for Pharma Stocks?

Eli Lilly & Co. LLY, -0.27% said Monday it will invest $700 million in a new facility in Boston aimed at developing RNA-based therapies. The company expects to have 250 scientists working at the site within the next five years.

Lilly to spend $700 million on Boston facility to develop RNA therapies

INDIANAPOLIS, Feb. 22, 2022 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700 million to establish a state-of-the-art facility at a new site in the Boston Seaport. This investment – part of the company's strategy to advance RNA based therapeutics – builds on the 2020 acquisition and rapid expansion of Prevail Therapeutics, a gene therapy pioneer based in New York City.

Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site

Patients with moderately-to-severely active ulcerative colitis (UC) who took Eli Lilly And Co's (NYSE: LLY) mirikizumab achieved statistically superior clinical remission rates at 12 weeks compared to placebo. The LUCENT-1 Phase 3 study of 1,162 patients included patients who had never tried a biologic treatment (biologic-naïve) and harder-to-treat patients who had previously taken a biologic that failed.

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

INDIANAPOLIS, Feb. 18, 2022 /PRNewswire/ -- Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab achieved statistically superior rates of clinical remission at 12 weeks compared to patients taking placebo in Eli Lilly and Company's (NYSE: LLY) pivotal LUCENT-1 Phase 3 study. Patients who took mirikizumab also achieved statistically significant improvements across key secondary endpoints including clinical, symptomatic, endoscopic and histologic (cellular level of tissue) measures, compared to those taking placebo.

Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study

Shares of Eli Lilly have dropped 15% since their highs in December.

After A 15% Drop, Eli Lilly Is Still Too Expensive

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co's (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals. The ICER released its report, giving evidence for the drug a “B+” rating and saying, “the evidence provides high certainty that tirzepatide delivers at least a small net health benefit when added to background therapy, with the possibility of a substantial net health benefit.

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

GlaxoSmithKline

GSK vs. LLY: Which Stock Is the Better Value Option?

GSK vs. LLY: Which Stock Should Value Investors Buy Now?

ImmunoGen

ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.

ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B

INDIANAPOLIS, Feb. 16, 2022 /PRNewswire/ -- Breast cancer is a complex disease with many factors that influence whether the cancer will return or spread, yet few resources exist to help people diagnosed with breast cancer understand these risk factors. In recognizing the need for more education about breast cancer recurrence, Eli Lilly and Company (NYSE: LLY) today launched a new education campaign in collaboration with Breastcancer.org, For the Breast of Us, Living Beyond Breast Cancer, and Susan G.

Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence

ImmunoGen Inc (NASDAQ: IMGN) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY) to grant exclusive rights to research, develop, and commercialize antibody-drug conjugates (ADCs) directed to targets selected by Lilly based on ImmunoGen's camptothecin technology. Camptothecins are an important class of anticancer drugs targeting Type I topoisomerase.

Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B

ImmunoGen Inc. shares IMGN, -3.82% jumped 7% in premarket trade Tuesday, after the company announced a license agreement with Eli Lilly & Co. LLY, -0.03% of its Novel Camptothecin ADC Platform for up to $1.7 billion in potential payments. Camptothecins are a class of cancer drugs.

ImmunoGen shares jump 7% premarket on news of license deal with Lilly worth up to $1.7 billion

Lilly's (LLY) new antibody-drug, bebtelovimab is authorized to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease

Lilly's (LLY) COVID-19 Drug Gets FDA Nod for Emergency Use

Abbott Labs

Amgen

Baxter

Cerner

Quest Diagnostics

Pfizer

Stryker

UnitedHealth Group

If any investor has stood the test of time, it is Warren Buffett, and with good reason.

10 Health Care Stocks Warren Buffett Owns That Offer Safety and Dependable Dividends

The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized bebtelovimab for emergency use in patients with mild-to-moderate COVID-19 who are at high risk of progression to severe disease, including hospitalization or death.

Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19

A US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody, voting 14-1 against approval. Hangzhou's Huadong Medicine acquired Asia-Pacific (ex-Japan) rights to a bi-functional immunotherapy from Akso Biopharma of Menlo Park, CA, in a $75 million agreement.

Week In Review: U.S. FDA Rejects Innovent/Lilly PD-1 NDA Based On China-Only Trial Subjects

Eli Lilly and Company ( LLY , Financial) announced on Friday that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant of Covid-19.

Eli Lilly Antibody Granted FDA Approval

Eli Lilly & Co. lly said late Friday that the U.S. Food and Drug Administration has issued an emergency-use authorization for bebtelovimab, the pharma company's antibody treatment for COVID-19. Bebtelovimab now can be used for the treatment of mild-to-moderate COVID-19 in adults as well as children older than 12 years of age and over a certain weight who are at high risk of severe COVID-19 and for whom treatment options may be limited.

Lilly's COVID-19 treatment gets FDA's emergency-use approval

The U.S. has ordered 600,000 doses of a new treatment that helps the immune system combat the coronavirus' omicron variant.

FDA Authorizes Eli Lilly Antibody Treatment That Fights Omicron

INDIANAPOLIS, Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY) announced today. Bebtelovimab can now be used for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19

The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients. The monoclonal antibody treatment sintilimab injection combined with pemetrexed and platinum chemotherapy is for the first-line treatment of people with non-squamous non-small cell lung cancer.

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

Investors should expect to see fewer Food and Drug Administration approvals of copycat PD-L1 therapies after an advisory committee recommended against approving an experimental cancer drug, according to SVB Leerink analysts. The drug in question, sintilimab, is being developed by Innovent Biologics Inc. 1801, -7.47% , a Chinese drug maker, and Eli Lilly & Co. LLY, -1.56%.

SVB Leerink analyst doesn't expect cancer drug developed by Innovent and Lilly to be approved

An FDA advisory for Lilly's (LLY) partner Innovent Biologics calls for conducting a new study on its first-line lung cancer candidate, sintilimab, for gaining approval for the same in the United States.

Lilly (LLY) Gets FDA Panel Advice for New Study on Sintilimab

FDA committee members said the trial population of mostly Asian men did not represent the diversity of U.S. patients.

News for Eli Lilly Stock (LLY)